SCHEMBL6888015

SCHEMBL6888015

CCC(=O)Oc1ccc(C=CC=C2SC(=S)N(CC(=O)O)C2=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 8/20 0.69
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
MAPT P10636 2/20 0.69
ALDH1A1 P00352 2/20 0.69
NPC1 O15118 1/20 0.69
PTPN1 P18031 3/20 0.54
MMP3 P08254 2/20 0.54
MMP13 P45452 2/20 0.54
PSMD14 O00487 1/20 0.52
PKM P14618 1/20 0.52
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
PTPN12 Q05209 1/20 0.50
PTPN22 Q9Y2R2 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888013 1.00 AKR1B1 (0.69) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL6887580 0.84 AKR1B1 (0.67) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL7537933 0.84 MAPT (0.80) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL4863223 0.84 MAPT (0.80) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL6887671 0.83 AKR1B1 (0.66) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL6885279 0.82 AKR1B1 (0.71) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL1315178 0.82 MAPT (1.00) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL10492259 0.82 MAPT (1.00) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL6887148 0.82 MAPT (0.73) AKR1B1MEN1KMT2AMAPTALDH1A1
SCHEMBL6885966 0.82 KMT2A (0.80) AKR1B1MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 US disclosed
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD 2003-02-13 US disclosed
EP-1117655-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS Esswein, Angelika (DE) 2001-07-25 EP disclosed
WO-2000018747-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders NR1H4, NR1D1, NR1I2 AKR1B1 417/4885MEN1 838/4885KMT2A 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.